Coherus Biosciences | CHRS - Actif À Court Terme





Actif À Court Terme Changement Date
AbbVie USD 33.67B 140M 2026-06
Acadia Pharmaceuticals USD 1.22B 128.53M 2026-06
Akebia Therapeutics USD 229.55M 13.93M 2026-06
ALKERMES USD 1.52B 164.26M 2026-06
Alnylam Pharmaceuticals USD 4.62B 400.86M 2026-06
Amarin USD 602.76M 23.26M 2026-06
Amgen USD 34.96B 3.49B 2026-06
Baxter International USD 6.99B 142M 2026-06
Biogen USD 7.31B 1.88B 2026-06
BioMarin Pharmaceutical USD 3.97B 633.45M 2026-06
Bristol-Myers Squibb USD 28.58B 1.37B 2026-06
Coherus Biosciences USD 133.79M 72.25M 2026-06
Eli Lilly USD 64.67B 9.84B 2026-06
Fujifilm JPY 1.72T 2.2B 2026-03
Gilead Sciences USD 12.53B 6.11B 2026-06
Ironwood Pharmaceuticals USD 332.29M 58.11M 2026-03
Merck USD 36.68B 1.66B 2026-06
Myriad Genetics USD 289M 23.8M 2026-06
Pacira USD 615.21M 100.25M 2026-06
Perrigo USD 2.45B 260.7M 2026-06
Pfizer USD 41.36B 1.46B 2026-06
PTC Therapeutics USD 2.62B 363.36M 2026-06
Regeneron Pharmaceuticals USD 18.45B 236.8M 2026-06
Sarepta Therapeutics USD 2.22B 86.05M 2026-06
Teva Pharmaceutical Industries USD 13.76B 50M 2026-06
Vertex Pharmaceuticals USD 12.54B 813.4M 2026-06
Xencor USD 523.21M 40.36M 2026-06
Zoetis USD 6.36B 118M 2026-06